Haystack MRD™ by Quest Diagnostics® will be attending the 2024 American Association for Cancer Research (AACR) annual meeting taking place April 5–10, 2024 in San Diego, CA. The AACR annual meeting stands as the cornerstone of the cancer research community, serving as a gathering point for scientists, clinicians, healthcare practitioners, survivors, patients, and advocates. This event provides a platform for sharing the most recent breakthroughs in cancer science and medicine. Covering a wide spectrum from population science and prevention to cancer biology, translational, and clinical studies, as well as survivorship and advocacy, the AACR annual meeting showcases the pioneering efforts of top-tier researchers worldwide.
About Haystack MRD™
Haystack MRD can provide insights into treatment decisions by detecting circulating tumor DNA (ctDNA) to identify any residual cancer cells after curative-intent treatment, such as surgery. Haystack uses a tumor-informed approach with a personalized test panel designed for each patient. Powered by Haystack’ technology, the test reduces background noise to detect ultralow numbers of ctDNA molecules in blood. Our higher level of precision science translates to improved minimal residual disease (MRD) detection and more confident treatment decisions.
Why choose Haystack MRD?
Our technology, designed by cancer research pioneers, was purpose-built to detect ultralow levels of ctDNA and offers the highest level of precision science.
Haystack MRD is powered by an optimized version of the ctDNA detection technology used in the DYNAMIC study to demonstrate the clinical benefit of MRD testing in patients with early-stage cancer. The DYNAMIC study was the first to provide clinical support for using ctDNA-based MRD testing to guide adjuvant therapy decisions.
With the addition of Haystack MRD, Quest Diagnostics includes MRD detection in its full range of oncology offerings for easier, more streamlined patient care.
Learn more at AACR 2024
To connect at AACR 2024, stop by booth 548 or get in touch today to schedule a meeting
This test was developed and its analytical performance characteristics have been determined by Haystack Oncology. It has not been cleared or approved by FDA. This assay has been validated pursuant to the CLIA regulations and is used for clinical purposes.
